Qdenga: India’s first dengue vaccine gets DCGI nod

Qdenga: India’s first dengue vaccine gets DCGI nod and is now officially approved for use in the country. The Drug Controller General of India (DCGI) has given its green signal for Qdenga, making it the first dengue vaccine available in India. Developed by Japanese pharmaceutical company Takeda, this vaccine is approved for individuals aged 4 to 60 years.

The DCGI clearance for Qdenga marks a significant milestone in India’s fight against dengue, a mosquito-borne viral disease that affects thousands annually. Qdenga is a live-attenuated vaccine designed to provide protection against all four serotypes of the dengue virus. Clinical trials have shown its efficacy in reducing severe dengue cases and hospitalizations.

With India approving the first dengue vaccine Qdenga, healthcare experts believe it could be a game-changer in public health. The vaccine will be administered in two doses, three months apart. It is recommended for both people who have had dengue before and those who have not, offering a broad shield against the disease.

The approval of Qdenga in India comes after rigorous evaluation of its safety and effectiveness. Takeda has committed to ensuring the vaccine’s affordability and availability across the country. This step is expected to help reduce the burden on hospitals during peak dengue seasons.

In conclusion, the DCGI nod for Qdenga is a welcome development for India, where dengue remains a persistent health challenge. With the first dengue vaccine now approved, the nation takes a crucial step toward better prevention and control of this disease.